Barinthus Biotherapeutics (BRNS) FCF Margin (2020 - 2024)

Barinthus Biotherapeutics has reported FCF Margin for 5 years, with the latest figure at 122.33% in Q3 2024.

• For the quarter ending Q3 2024, FCF Margin changed N/A year-over-year to 122.33%; the trailing twelve-month figure through Dec 2025 stood at 320.77% (down 12148.0% YoY), and the FY2024 full-year result was 199.29%, up 616131.0% from the prior year.
• FCF Margin for Q3 2024 stood at 122.33%, up from 4555.69% in the prior quarter.
• The five-year high for FCF Margin was 839600.0% in Q4 2021, with the low at 40691.43% in Q2 2021.
• Historically, FCF Margin has averaged 51476.3% across 5 years, with a median of 474.76% in 2020.
• Annual changes were most pronounced in 2021 — FCF Margin surged 84103814 bps — and 2022, when it tumbled 83978475 bps.
• Barinthus Biotherapeutics' FCF Margin stood at 1438.14% in 2020, then jumped by 58481 bps to 839600.0% in 2021, then plunged by 100 bps to 184.75% in 2022, then plunged by 2366 bps to 4555.69% in 2023, then jumped by 97 bps to 122.33% in 2024.
• The last three FCF Margin figures came in at 122.33% (Q3 2024), 4555.69% (Q2 2023), and 1158.33% (Q1 2023), per Business Quant data.